Supreme Court Sides With Generics in ‘Skinny Label’ Dispute

The U.S. Supreme Court has ruled in favor of Hikma Pharmaceuticals in a closely watched patent dispute involving a generic version of Amarin Pharma's blockbuster cardiovascular drug Vascepa, finding that Amarin failed to adequately plead a claim of patent infringement through active inducement.

In a decision reversing the U.S. Court of Appeals for the Federal Circuit, the high court’s 6/4-issued opinion held that Amarin's allegations did not plausibly establish that Hikma encouraged physicians to prescribe its generic icosapent ethyl product for patented uses of Vascepa.

The dispute centered on whether Hikma's marketing and labeling practices could be viewed as inducing doctors to prescribe the generic drug for cardiovascular risk reduction in certain statin-treated patients, an indication still protected by Amarin patents. Hikma had launched its product with a so-called "skinny label" that carved out the patented use while retaining approval for the treatment of severe hypertriglyceridemia.

Writing for the court, the justices concluded that Amarin's theory relied on a speculative chain of events. The opinion stated that while it was "possible" that physicians could prescribe Hikma's generic product to patients already taking statins, such allegations alone did not make active inducement a "plausible" claim under federal pleading standards established by the Supreme Court's earlier decision in Ashcroft v. Iqbal.

"Without more," the Court wrote, Amarin's allegations failed to support a plausible inference that Hikma specifically intended to encourage infringement of the patents.

The ruling means Amarin's complaint cannot survive Hikma's motion to dismiss under Rule 12(b)(6) of the Federal Rules of Civil Procedure. The Supreme Court reversed the Federal Circuit's judgment and remanded the case for further proceedings consistent with its opinion.

In an earlier brief that supported the Supreme Court’s decisional outcome, the U.S. Department of Justice (DoJ) said (see story) the Federal Circuit’s ruling on on skinny labels threatened to undermine the Hatch-Waxman framework for bringing generics to market by exposing compliant generic manufacturers to inducement claims based on ordinary, non-infringing behavior. The DoJ amicus brief argued that the appeals court erred by finding that general statements about a generic drug could plausibly constitute inducement of infringement. Under settled law, inducement requires credible allegations that the defendant encouraged specific infringing conduct — i.e., prompting a prescriber to use a drug in a way that violates a patent, the government contended, adding that simple truthful references to a drug do not meet that standard.

A separate brief by the Association for Accessible Medicines also argued that the Federal Circuit’s decision improperly undermines the skinny label framework. The generic drug lobbying group said Congress designed the skinny-label pathway so generic entrants can avoid patent disputes for carved-out uses. Labels that comply with FDA requirements should not, by themselves, expose generics to accusations of inducing infringement.

The opinion is expected to have significant implications for pharmaceutical patent litigation involving skinny-label generic drugs. Brand-name manufacturers have increasingly relied on inducement claims to challenge generic competitors that omit patented indications from their FDA-approved labels but may still benefit from physician prescribing practices. The Court's ruling raises the bar for pleading such claims, requiring more concrete allegations that a generic manufacturer actively encouraged infringement rather than merely benefiting from it.

The case has been closely watched by both branded and generic drug makers because it addresses the balance between patent protections for approved drug uses and the regulatory pathway that allows generic manufacturers to market products for unpatented indications.